Tirzepatide 5mg — Vial Spec, Reconstitution Math & COA

Overview of the 5mg Tirzepatide Research Vial

A 5mg vial of research-grade tirzepatide contains a lyophilized solid cake comprising exactly 5.0 milligrams of pure active peptide monomer, balanced with appropriate buffer salts or bulking agents such as mannitol to ensure structural stability during vacuum drying. In laboratory settings, the 5mg vial size represents an optimal mass for targeted, medium-scale bench assays, single-cohort animal studies, or preliminary receptor-binding screens where larger bulk quantities would risk degradation through repeated ambient exposure or extended solution storage.

Investigators select the 5mg mass specification to balance volumetric accuracy with batch efficiency. When reconstituted, a 5mg mass yields workable concentrations for micro-pipetting into cell culture plates or micro-osmotic pump reservoirs. If your laboratory requires specific volume configurations, explore our complete catalog of research peptides or review dedicated dual-agonist offerings such as GLP-1/GIP receptor research compounds to match your experimental scale.

Preclinical Mechanism of Dual GIP/GLP-1 Receptor Agonism

Tirzepatide is a novel synthetic peptide engineered as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Structurally, it is a 39-amino-acid peptide sequence modified with a C20 fatty diacid diacyl moiety via a linker attached to the Lys20 residue. Preclinical studies suggest that this dual-receptor targeting produces synergistic downstream intracellular signaling compared to single-receptor activation models.

In vitro functional assays demonstrate that tirzepatide exhibits balanced affinity for the native GIP receptor while demonstrating biased agonist activity at the GLP-1 receptor, favoring cyclic adenosine monophosphate (cAMP) generation over beta-arrestin recruitment. In rodent models of metabolic dysregulation, exposure to dual GIP/GLP-1 agonism yields marked modulation of lipid synthesis, enhanced insulin release in response to glucose challenges, and alterations in central satiety signaling circuits within the hypothalamus.

Technical Specifications & Chemical Identity

To ensure precise experimental reproducibility, laboratory investigators must confirm the molecular parameters of the compound prior to assay integration. Tirzepatide possesses a chemical formula of C225H348N48O68 and a calculated molecular weight of approximately 4813.45 Da. It is synthesized using solid-phase peptide synthesis (SPPS) protocols, followed by reverse-phase high-performance liquid chromatography (RP-HPLC) purification to achieve a chemical purity target of ≥98.0%.

The finished compound is isolated as a trifluoroacetate (TFA) or acetate salt formulation. Because residual counterions and moisture content influence total dry mass measurement, lot-specific analytical documentation must be reviewed to adjust volumetric mass calculations during high-precision quantitative chemistry. Every lot manufactured for PX1 Research undergoes stringent mass spectrometry (MS) sequence verification to confirm exact amino acid composition and structure.

Reconstitution Protocols & Concentration Calculations

Reconstitution of a 5mg tirzepatide vial requires sterile, laboratory-grade diluents—typically Bacteriostatic Water (0.9% benzyl alcohol) for multi-use analytical sampling over a 28-day window, or Sterile Normal Saline (0.9% NaCl) for immediate in vitro assays sensitive to preservative toxicity. The addition of diluent must be conducted by directing liquid stream along the inner glass wall of the vial to avoid mechanical shear stress and foam formation.

To calculate working concentrations for a 5mg vial, use the basic formula: Concentration (mg/mL) = Mass (mg) / Volume (mL).

• Reconstituting 5mg with 1.0 mL diluent yields a final concentration of 5.0 mg/mL (5.0 µg/µL). • Reconstituting 5mg with 2.0 mL diluent yields a final concentration of 2.5 mg/mL (2.5 µg/µL). • Reconstituting 5mg with 3.0 mL diluent yields a final concentration of 1.67 mg/mL (1.67 µg/µL).

For precise aliquot design and custom volumetric concentrations, researchers can utilize the PX1 reconstitution calculator to determine micro-liter additions for target dosage vectors in preclinical models.

Aliquoting Strategy & Freeze-Thaw Degradation Management

Peptide monomers in aqueous solution are subject to physical and chemical degradation pathways, including oxidation of methionine residues, deamidation of asparagine, and non-covalent aggregation. Subjecting a reconstituted 5mg tirzepatide solution to repeated freeze-thaw cycles significantly accelerates aggregate formation, leading to potential loss of potency and inconsistent experimental results.

To maximize stability, investigators should perform an immediate aliquoting procedure post-reconstitution. Transfer the reconstituted solution into sterile, low-protein-binding micro-centrifuge tubes in single-use volumetric fractions (e.g., 50 µL to 200 µL). These aliquots should be snap-frozen in liquid nitrogen or an ethanol-dry ice bath prior to long-term freezer placement, ensuring that individual working samples are thawed only once immediately before assay administration.

Storage Protocols for Lyophilized and Reconstituted Peptides

Lyophilized tirzepatide 5mg vials must be stored in temperature-controlled environments to preserve peptide integrity prior to use. Short-term storage (1–3 months) at 2°C to 8°C is acceptable for active laboratory workflows. For long-term archiving (>3 to 24 months), lyophilized vials should be kept in a desiccated freezer environment at -20°C or -80°C, protected from light exposure.

Once reconstituted, aqueous tirzepatide prepared with bacteriostatic water remains stable at 2°C to 8°C for up to 28 days. Solution prepared with unpreserved sterile water or saline must be used immediately or aliquoted and stored at -80°C. Storage in frost-free freezers is strictly disincentivized due to temperature cycling during auto-defrost runs.

Analytical Verification: HPLC, Mass Spectrometry & Endotoxin Limits

Quality assurance for research peptides demands rigorous analytical validation. PX1 Research enforces a strict multi-tier testing regimen for every lot of tirzepatide produced. Purity is validated via RP-HPLC, ensuring peak area integration yields ≥98% monomer purity without significant secondary degradation peaks. Mass spectrometry via Electrospray Ionization (ESI-MS) confirms the exact molecular weight against theoretical parameters.

In addition to purity and identity, biological assays demand low endotoxin levels to prevent non-specific inflammatory responses in cellular models or animal tissues. Every lot is subjected to Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels reside strictly below <0.01 EU/mg. Institutional researchers can inspect verified lot-matched documentation directly in our public lot-specific COA database.

Comparative Analysis: Tirzepatide vs. Related Incretin Mimetics

When designing comparative metabolic research protocols, investigators frequently evaluate tirzepatide alongside mono-agonist and tri-agonist research compounds. The table below highlights key functional distinctions across commonly evaluated incretin receptor research peptides:

In vitro receptor-binding assays demonstrate that while single-agonist compounds like Semaglutide bind selectively to the GLP-1 receptor, dual-acting tirzepatide recruits both GIP and GLP-1 downstream pathways. Emerging triple-agonist compounds such as Retatrutide further extend this profile by incorporating glucagon receptor (GCGR) activity. Additionally, historical baseline data from legacy agents like Liraglutide provide valuable comparative controls for binding affinity and pharmacokinetic half-life studies.

Selecting Vial Mass: 5mg vs. 10mg vs. Larger Formulations

Determining whether a 5mg vial or a larger 10mg/15mg unit is appropriate depends on experimental scale, sample handling protocols, and financial constraints. A 5mg vial is ideal for small pilot studies, exploratory in vitro screens, or procedures requiring fresh solution preparation every few days to minimize solution degradation.

Larger research facilities conducting high-throughput screening or high-density rodent cohorts often prefer higher unit masses to simplify stock solution preparation. However, if reconstituting larger masses results in solution storage exceeding 30 days, multiple 5mg vials are superior for maintaining structural stability. For high-volume institutional orders and tailored research supply agreements, explore options through our dedicated wholesale research account portal.

PX1 Research Quality Standards & USA Supply Chain Security

PX1 Research operates as a premier USA-based supplier of high-purity research compounds, adhering strictly to institutional quality requirements. All peptide products are synthesized in GMP-compliant facilities and verified by independent ISO 17025 accredited analytical laboratories within the United States. We enforce complete transparency, pairing every batch fill size with a downloadable, lot-matched COA.

To ensure supply chain continuity and prevent temperature-induced degradation during transport, PX1 dispatches all orders directly from state-of-the-art fulfillment hubs in California and Arizona. Orders placed Monday through Friday before cut-off times ship same-day under climate-controlled packing conditions, delivering reliable raw materials to academic, pharmaceutical, and biotechnology research facilities nationwide.